Alvogen is pleased to announce the appointment of Joo-Hyung Lee as CEO of Kunwha Pharmaceuticals in South-Korea.
Joo-Hyung will be leading Kunwha Pharmaceuticals to become a major player in the dynamic Korean pharmaceutical market and will develop Kunwha as a hub for manufacturing and R&D for the Asia Pacific region. Joo-Hyung has over two decades of experience in the Korean pharmaceuticals industry, both in multinational and domestic Korean companies. He has a strong marketing and sales background, with an outstanding track record. Joo-Hyung's last position was Senior Vice President & Chief of Strategic Marketing Office at a leading Korean pharmaceutical company. He received a bachelor’s degree in pharmaceutical science and an MBA at Georgetown University.
Alvogen acquired a majority share in Kunwha Pharmaceuticals last October, as a further step in its strategy to establish a presence in attractive generic pharmaceutical markets globally.
"We are very excited to have Joo-Hyung Lee on board heading up a dynamic team at Kunwha", commented Peter Keil, Alvogen's Executive Vice President for Asia. "He brings a wealth of experience in the industry and I know will make an invaluable addition to the Alvogen family".